Disease / condition

Peripheral T-cell Lymphoma clinical trials

Free access to 40 studies·10+ countries·Updated daily11 recruiting
40
Total trials
10+
Countries
10+
Sponsors
11
Recruiting
By phase
Phase 218
Phase 16
Phase 35
N/A4
Phase 1/23
By status
Completed16
Recruiting11
Not yet recruit...4
Unknown4
No longer avail...2
Top countries
China15
Japan3
United States of America3
South Korea2
Italy2
Top sponsors
Ruijin Hospital3
Acrotech Biopharma...3
Mingzhi Zhang2
Solasia Pharma K.K...2
Sun Yat-sen Univer...2
Recent trials
Latest clinical trials for Peripheral T-cell Lymphoma
NCT06422247Recruiting
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
Bristol-Myers SquibbJapan
NCT06421948·Phase 1/2Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
Yanyan LiuChina
NCT05949944·Phase 1/2Not yet recr...
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Sun Yat-sen University
NCT05458180·Phase 1Not yet recr...
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma
Tianjin Medical University Can...China
NCT04880746·Phase 3Recruiting
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
Ruijin HospitalChina
NCT04615468·Phase 2Not yet recr...
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL)
Chia Tai Tianqing Pharmaceutic...China
NCT04569032·Phase 2Recruiting
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.France,Italy,Spain,United Kingdom,United States of America
NCT04512534·Phase 2Recruiting
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
Fudan UniversityChina
NCT04480125·Phase 2Recruiting
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
Ruijin HospitalChina
NCT04480099·Phase 2Recruiting
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
Ruijin HospitalChina
NCT04444141·Phase 1/2Recruiting
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma
AkesoChina
2019-001123-13No longer av...
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Verastem, Inc.
NCT04052659·Phase 2Not yet recr...
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Peking UniversityChina
NCT04040491·Phase 4Recruiting
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
Mingzhi ZhangChina
NCT03952572·Phase 3Recruiting
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma
Peking UniversityChina
NCT03553537·Phase 3
Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Southwest Hospital, China
NCT03372057·Phase 2Active, not ...
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
SecuraBioGermany,Italy,United Kingdom,United States of America
NCT03212937·Phase 1Completed
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
National Cancer Centre, Singap...Singapore
NCT03321890·Phase 2
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Sun Yat-sen UniversityChina
NCT02809573·Phase 1Completed
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
Chipscreen Biosciences, Ltd.China
About this record

Access comprehensive clinical trial information for Peripheral T-cell Lymphoma through Pure Global AI's free database. This collection includes 40 clinical trials across multiple phases including Phase 2, Phase 1, Phase 3. Currently, 11 trials are actively recruiting participants.

Research for Peripheral T-cell Lymphoma is being conducted in China, Japan, United States of America and 7+ other countries. Leading sponsors include Ruijin Hospital and Acrotech Biopharma Inc.. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.

Pure Global AI provides free access to 40 clinical trials studying Peripheral T-cell Lymphoma, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.

The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.

Top research sponsors include Ruijin Hospital, Acrotech Biopharma Inc., Mingzhi Zhang, among others.